HEALEY ALS Platform Trial - Regimen C CNM-Au8

Completed · Phase 2/Phase 3 · Has a placebo group

Conditions studied: Amyotrophic Lateral Sclerosis

In brief

The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS. Regimen C will evaluate the safety and efficacy of a single study drug, CNM-Au8, in participants with ALS.

Key facts

Study ID

NCT04414345

Run by

Merit E. Cudkowicz, MD

People needed

161

Starts

2020-07-30

Expected to finish

2023-03-07

Last updated by the study team

2023-07-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• No additional inclusion criteria beyond the inclusion criteria specified in the Master Protocol (NCT NCT04297683).

You may not qualify if…

• The following exclusion criterion is in addition to the exclusion criteria specified in the Master Protocol (NCT NCT04297683).
• History of allergy to gold, gold salts, or colloidal gold preparations.

Where it is running

• Healey Center for ALS at Mass General — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.